Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

It's been a volatile year for the company, but don't let that scare you away.

CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group ...

China’s nascent challenge has U.S. biotech startups hustling to emulate China’s efficiency and speed in drug development.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the ...

Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder ...

Another wave of layoffs has hit one of the Bay Area's biggest biotech companies—and the latest cuts push a troubling trend ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...